AngioDynamics, Inc. (NASDAQ:ANGO) CEO Purchases 10,000 Shares

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) CEO James C. Clemmer acquired 10,000 shares of the stock in a transaction on Monday, April 8th. The stock was acquired at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the acquisition, the chief executive officer now directly owns 539,066 shares in the company, valued at approximately $3,611,742.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

AngioDynamics Stock Down 6.0 %

Shares of AngioDynamics stock traded down $0.42 on Monday, hitting $6.61. The company's stock had a trading volume of 1,217,286 shares, compared to its average volume of 568,944. The firm has a fifty day moving average price of $5.84 and a 200-day moving average price of $6.49. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $11.38. The company has a market capitalization of $263.41 million, a P/E ratio of -1.37 and a beta of 0.66.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Friday, January 5th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. AngioDynamics had a negative net margin of 60.21% and a negative return on equity of 3.49%. The company had revenue of $79.07 million for the quarter, compared to the consensus estimate of $81.65 million. As a group, analysts expect that AngioDynamics, Inc. will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds have recently bought and sold shares of the stock. Gladius Capital Management LP acquired a new stake in shares of AngioDynamics during the third quarter valued at $30,000. Point72 Hong Kong Ltd acquired a new stake in shares of AngioDynamics during the 1st quarter worth about $36,000. US Bancorp DE grew its holdings in shares of AngioDynamics by 63.3% during the second quarter. US Bancorp DE now owns 3,691 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 1,431 shares in the last quarter. Quarry LP raised its position in shares of AngioDynamics by 227.4% in the first quarter. Quarry LP now owns 3,899 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 2,708 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in shares of AngioDynamics during the third quarter valued at approximately $41,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Oppenheimer raised AngioDynamics from a "market perform" rating to an "outperform" rating and set a $12.00 target price for the company in a report on Friday. Raymond James decreased their price objective on shares of AngioDynamics from $12.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, January 9th. Finally, HC Wainwright dropped their target price on shares of AngioDynamics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Monday, January 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, AngioDynamics presently has an average rating of "Moderate Buy" and a consensus target price of $14.25.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.